Top Tweets for #elpiscience
🇨🇳 #Elpiscience Biopharmaceuticals filed its second application for a #HKSE #IPO, which has now been accepted, and its prospectus has been published. https://t.co/HYjrQ5kvmp
Founded in 2017, Elpiscience has a pipeline consisting of 6 key assets, including 4 in clinical stages and 2 in preclinical development.
Its core candidate, ES102, is a hexavalent OX40 agonist antibody, constructed by fusing nanobodies with Fc domains. Its multivalent design is intended to overcome cross-linking limitations, enabling potent agonistic activity. In early clinical studies, ES102 combined with PD-1 antibodies has demonstrated promising efficacy in treating head and neck cancer and NSCLC.
ES104 (Tovecimig) is a VEGF/DLL4 bispecific antibody originally developed by ABL Bio and later licensed to TRIGR Therapeutics. Elpiscience subsequently obtained the Greater China rights from TRIGR.
Elpiscience has also developed the BiME bispecific antibody platform, which works by recruiting macrophages to kill tumor cells. In late 2023, the company entered into a collaboration with Astellas Pharma, granting licenses to its BiME platform as well as two product candidates, ES019 and another undisclosed molecule.
Since its founding, Elpiscience has completed four rounds of financing, raising a total of $251.5 million (approximately RMB 1.79 billion). Following its Series C round in February 2021, the company was valued at $599 million.
#Elpiscience Announces First Patient Dosed in Phase 1/2 Clinical Study of #ES104 for Treatment of #ColorectalCancer https://t.co/KCvMvu9xUB
#Elpiscience Announces #CDE Clearance of #IND Application for #AntiCD39 #MonoclonalAntibody #ES002 https://t.co/58WYuFOSPF
#Elpiscience Announces First Patient Dosed in US Phase I Clinical Trial of #AntiCD39 #MonoclonalAntibody #ES002 for Treatment of Advanced #SolidTumors https://t.co/5BI59Zb1oB
Exciting clinical progress for patients! #Elpiscience #immunotherapy #oncology
https://t.co/UXuRKERGXU
Great pretaped panel on #chinese #biotech financing and predictions at #biotechshowcase Tony Chen @JonesDay @bradloncar Alex J. Zhang #ChineseAmericanBiopharmaceuticalSociety Kim Nearing #elpiscience @Sujuan_Ba
#Elpiscience Announces the Completion of $105 Million Series C Financing https://t.co/sEJsMruhN7
#Elpiscience Completes Series B Financing of USD $100 Million https://t.co/3LuBjv21YU
Great networking at #ChinaShowcase @ChinaBio in San Francisco - With the evolving market in #China, how can companies best leverage partners & strategically position themselves for growth? @ChinaBio @HoganLovells #Elpiscience #ShenzhenBio #SalubrisBio #PullanConsulting
Last Seen Hashtags on Sotwe
olderman
Seen from United Kingdom
spiderswipe
Seen from United States
cumtributevn
Seen from Vietnam
BoloArtesanal
Seen from United States
CampfireCheers
Seen from United States
BoseConnect
Seen from United States
adanaescort
Seen from Germany
NoLimit()filter:media() - filter:images
Seen from Turkey
videobokep
Seen from Indonesia
afghan sex
Seen from Pakistan
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.1M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.5M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.2M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.4M followers
KATY PERRY
@katyperry
88.8M followers
Taylor Swift
@taylorswift13
82.7M followers
Lady Gaga
@ladygaga
74.2M followers
Virat Kohli
@imvkohli
71.6M followers
Kim Kardashian
@kimkardashian
70.3M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.5M followers
Neymar Jr
@neymarjr
64.5M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.8M followers
Selena Gomez
@selenagomez
61.8M followers
X
@x
60.8M followers